I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-

Dated: August 18, 2008

Signature: /Cristin Cowles/

(Cristin Howley Cowles, Ph.D.)

Docket No.: KZY-002USRCE (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

David Deperthes et al.

Application No.: 10/551,977 Confirmation No.: 3931

Filed: October 4, 2005 Art Unit: 1643

For: PEPTABODY FOR CANCER TREATMENT Examiner: A. Gussow

MS RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Supplemental Information Disclosure Statement is filed concurrently with an Amendment and Response and a Request for Continued Examination (RCE).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicants have not submitted copies of U.S. patents and U.S. patent applications. Applicants submit herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2). Applicants note that references C5 – C7 on the enclosed SB08 form correspond to references cited in the International Search Report, which was included in the IDS submitted December 4, 2006.

Application No.: 10/551,977 Art Unit 1643

In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Supplemental Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

As this SIDS is being submitted concurrently with an RCE, it is Applicants' understanding that no additional fee is necessary for consideration of this SIDS. If Applicants' understanding is incorrect, however, the Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. KZY-002USRCE.

Dated: August 18, 2008 Respectfully submitted,

CHC By /Cristin Cowles/

Cristin Howley Cowles, Ph.D. Registration No.: 55,281 LAHIVE & COCKFIELD, LLP One Post Office Square Boston, Massachusetts 02109-2127

(617) 227-7400 (617) 742-4214 (Fax)

Attorney/Agent For Applicant